RT Journal Article
SR Electronic
T1 Rate of Force Development is Related to Maximal Force, Muscle Quality and Physical Function in Patients With Chronic Kidney Disease Predialysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19013557
DO 10.1101/19013557
A1 Jared M. Gollie
A1 Michael O. Harris-Love
A1 Samir S. Patel
A1 Marc R. Blackman
YR 2019
UL http://medrxiv.org/content/early/2019/12/11/19013557.abstract
AB Physical function is severely compromised in people with chronic kidney disease (CKD) and worsens with continued decreases in kidney function. Neuromuscular force capacity is a key determinant of physical function in healthy older adults, though its importance in persons with CKD is less understood. This study aimed to determine the relationships among rate of force development (RFD), muscle quality and physical function in a group of community-dwelling, middle-aged and older men (n=14; age=71.2±6.2 years) with CKD stages 3 and 4 (eGFR=37.5±10.4 ml/min per 1.73 m2). Force characteristics were determined from maximal knee extensor isometric contractions and muscle quality was estimated using ultrasound grayscale analysis. Physical function was assessed by the Short Physical Performance Battery (SPPB) and 5-repetition sit-to-stand (STS). eGFR was positively related to SPPB (r=0.54, p=0.044) and inversely related to STS (r=-0.62, p=0.029). RFD was positively related to SPPB at time points 0-50 ms, 50-100 ms, and 0-300 ms (RFD0-50, r=0.73, p=0.010; RFD50-100, r=0.67, p=0.022 and RFD0-300 r=0.61, p=0.045); and inversely related to STS at time points 0-50 ms, 50-100 ms, and 0-300 ms (RFD0-50, r=-0.78, p=0.007; RFD50-100, r=-0.78, p=0.006 and RFD0-300 r=-0.76, p=0.009), respectively. RFD was positively associated with maximal voluntary force (MVF) at time points 50-100 ms, 100-200 ms, and 0-300 ms (RFD50-100, r=0.72, p=0.011; RFD100-200,r=0.66, p=0.025; and RFD0-300 r=0.70, p=0.016). Neither MVF nor muscle quality was significantly associated with functional measures. These findings highlight the relationships between RFD and physical function in middle-aged and older men with CKD stages 3 and 4.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03160326Funding StatementThis study was conducted as part of a VA funded Center of Innovation award (VACI# AM-251) between the San Francisco VAMC and the Washington D.C. VAMC, the aim of which was to investigate clinically viable approaches for the assessment of sarcopenia in Veterans with CKD stages 3 and4 predialysis (ClinicalTrials.gov NCT03160326).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified, anonymized dataset will be created and shared upon the completion of the study protocol in accordance with VA policy.